Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 02, 2024 | May 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 02, 2024 · Filed May 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,485.82 |
Ending reported balance
After 2024-05-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-02 · Exercise / conversion · Acquired 29,350 · Balance 33,835.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Row 2 · 2024-05-02 · Sale · Disposed 12,207 · Balance 21,628.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2024-05-02 · Sale · Disposed 17,143 · Balance 4,485.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2024-05-10 | Direct | 0 |
Reported balance
After 2024-05-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-02 · Exercise / conversion · Disposed 29,350 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Living Trust | 4,038,377 |
Reported balance
Holding disclosure · report date 2024-05-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,038,377 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2024 Filed May 2, 2024 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-005500 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 2, 2024 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 17,143 | $84.59 | $1,450,126.37 |
DisclosureSEC source: 0001225208-24-005500 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2024 Filed May 2, 2024 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,207 | $85.02 | $1,037,839.14 |
DisclosureSEC source: 0001225208-24-005500 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,628.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2024 Filed May 2, 2024 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-24-005500 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-004959 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,350 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,618 | $92.70 | $1,540,488.60 |
DisclosureSEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $92.125 to $93.120. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,820 | $91.54 | $898,922.80 |
DisclosureSEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,103.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $91.120 to $92.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,712 | $93.72 | $254,168.64 |
DisclosureSEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,923.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $93.130 to $94.130. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 200 | $94.19 | $18,838.00 |
DisclosureSEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,635.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $94.185 to $94.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-24-004959 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 00:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-003505 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,700 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 00:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,040 | $87.05 | $1,396,282.00 |
DisclosureSEC source: 0001225208-24-003505 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $86.63 to $87.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 00:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,310 | $86.21 | $1,147,455.10 |
DisclosureSEC source: 0001225208-24-003505 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,525.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.62 to $86.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 00:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-24-003505 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 23:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-001597 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,050 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 23:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,167 | $87.55 | $1,065,220.85 |
DisclosureSEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $87.110 to $88.105. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 23:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,761 | $86.44 | $843,740.84 |
DisclosureSEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,652.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $86.100 to $87.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 23:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,422 | $88.63 | $569,181.86 |
DisclosureSEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,413.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $88.210 to $89.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 23:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,000 | $89.61 | $89,610.00 |
DisclosureSEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,835.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $89.390 to $90.080. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 23:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-24-001597 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-000480 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,400 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 26,850 | $72.94 | $1,958,439.00 |
DisclosureSEC source: 0001225208-24-000480 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.41 to $73.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $73.46 | $183,650.00 |
DisclosureSEC source: 0001225208-24-000480 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,335.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.42 to $73.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-24-000480 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-011072 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,750 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,722 | $75.12 | $1,030,796.64 |
DisclosureSEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $74.530 to $75.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,600 | $74.22 | $786,732.00 |
DisclosureSEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,207.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $73.520 to $74.515. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,200 | $73.15 | $234,080.00 |
DisclosureSEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,807.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $72.510 to $73.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,828 | $75.73 | $138,434.44 |
DisclosureSEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,007.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.560 to $75.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-23-011072 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| November 06, 2023 Filed Nov 6, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 371,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Living Trust Disclosed balance after: 4,038,377 F3 · acquired: In connection with an in-kind transfer of shares from the Reporting Person's 401(k) account to his Living Trust, the remaining 0.7321 of one share was automatically sold by the 401(k) plan administrator at a price of $63.505269 per share, for a total of $46.50, to comply with the plan administrator's policy prohibiting the transfer of a fractional share. Read SEC document |
| November 06, 2023 Filed Nov 6, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 371,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Indirect · 401(k) Disclosed balance after: 0 F3 · acquired: In connection with an in-kind transfer of shares from the Reporting Person's 401(k) account to his Living Trust, the remaining 0.7321 of one share was automatically sold by the 401(k) plan administrator at a price of $63.505269 per share, for a total of $46.50, to comply with the plan administrator's policy prohibiting the transfer of a fractional share. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-010019 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,100 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 29,350 | $67.18 | $1,971,733.00 |
DisclosureSEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $66.59 to $67.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-23-010019 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| October 02, 2023 Filed Oct 2, 2023 22:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-009136 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,450 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2023 Filed Oct 2, 2023 22:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 29,350 | $68.84 | $2,020,454.00 |
DisclosureSEC source: 0001225208-23-009136 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.39 to $69.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2023 Filed Oct 2, 2023 22:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-23-009136 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| September 05, 2023 Filed Sep 5, 2023 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008709 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,800 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 5, 2023 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 29,350 | $75.86 | $2,226,491.00 |
DisclosureSEC source: 0001225208-23-008709 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,485.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.40 to $76.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2023 Filed Sep 5, 2023 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-23-008709 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,835.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 49,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-008597 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Living Trust Disclosed balance after: 3,666,688 Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 49,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-008597 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,485.82 Read SEC document |
| August 07, 2023 Filed Aug 7, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-008065 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,150 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 7, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 29,050 | $79.86 | $2,319,933.00 |
DisclosureSEC source: 0001225208-23-008065 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,251.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $79.490 to $80.485. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2023 Filed Aug 7, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $80.54 | $24,162.00 |
DisclosureSEC source: 0001225208-23-008065 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,301.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.510 to $80.570. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2023 Filed Aug 7, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,350 | $36.75 | $1,078,612.50 |
DisclosureSEC source: 0001225208-23-008065 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,601.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,350 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-007306 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,500 Underlying: Common Stock · 29,350 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 21,728 | $90.63 | $1,969,208.64 |
DisclosureSEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,251.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.09 to $91.09 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,622 | $91.22 | $695,278.84 |
DisclosureSEC source: 0001225208-23-007306 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,979.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $91.10 to $91.50 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.